EGRX Sep 2022 50.000 call
| Previous close | 3.6100 |
| Open | 3.5200 |
| Bid | 1.1500 |
| Ask | 4.9000 |
| Strike | 50.00 |
| Expiry date | 2022-09-16 |
| Day's range | 2.1400 - 3.6100 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
- Simply Wall St.
Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- GlobeNewswire
Eagle Pharmaceuticals to Host Second Quarter 2022 Financial Results on August 9, 2022
WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 9, 2022Time8:30 a.m. ETToll free (U.S.)800-445-7795In
- Zacks
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.
